National comprehensive cancer network (NCCN) recommendations for drugs without US food and drug administration (FDA) approval in metastatic breast cancer: A cross-sectional study

被引：0
|
作者：
Etan, Tal [1 ]
Amir, Eitan [2 ]
Tibau, Adriana [3 ]
Yerushalmi, Rinat [4 ]
Moore, Assaf [4 ]
Shepshelovich, Daniel [1 ]
Goldvaser, Hadar [4 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[4] Rabin Med Ctr, Petah Tiqwa, Israel
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS14-13
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study
    Mooghali, Maryam
    Mitchell, Aaron P.
    Skydel, Joshua J.
    Ross, Joseph S.
    Wallach, Joshua D.
    Ramachandran, Reshma
    BMJ MEDICINE, 2024, 3 (01):
  • [12] Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study
    Wagner, Jeffrey
    Marquart, John
    Ruby, Julia
    Lammers, Austin
    Mailankody, Sham
    Kaestner, Victoria
    Prasad, Vinay
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
  • [13] Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
    Cherla, Avi
    Naci, Huseyin
    Kesselheim, Aaron S.
    Gyawali, Bishal
    Mossialos, Elias
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 490 - 498
  • [14] Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
    Parikh, Ravi B. B.
    Hubbard, Rebecca A. A.
    Wang, Erkuan
    Royce, Trevor J. J.
    Cohen, Aaron B. B.
    Clark, Amy S. S.
    Mamtani, Ronac
    JAMA ONCOLOGY, 2023, 9 (04) : 567 - 569
  • [15] US Food and Drug Administration Approval of Drugs for the Treatment of Prostate Cancer: A New Era Has Begun
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) : 362 - 364
  • [16] Use of bevacizumab after US Food and Drug Administration (FDA) approval for first-line metastatic colorectal cancer (mCRC): A Cancer Outcomes Research & Surveillance Consortium (CanCORS) study
    Zafar, Y.
    Grambow, S. C.
    Abbott, D. H.
    Schrag, D.
    Kolimaga, J. T.
    Conner, L. Z.
    Weeks, J. C.
    Provenzale, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [17] Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
    Joshua D. Wallach
    Anita T. Luxkaranayagam
    Sanket S. Dhruva
    Jennifer E. Miller
    Joseph S. Ross
    BMC Medicine, 17
  • [18] Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
    Wallach, Joshua D.
    Luxkaranayagam, Anita T.
    Dhruva, Sanket S.
    Miller, Jennifer E.
    Ross, Joseph S.
    BMC MEDICINE, 2019, 17 (1)
  • [19] Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM)
    Lepisto, E. M.
    Tangirala, K.
    Vandergrift, J. L.
    McClure, J. S.
    McNally, D. L.
    Mullins, C. D.
    Seal, B. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [20] Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer
    Yamashita, Kenji
    Kaneko, Masayuki
    Narukawa, Mamoru
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (09) : 1193 - 1200
12345